Low-dose enzalutamide for advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This study looks at how well a lower dose of the medication enzalutamide works and how tolerable it is for men with advanced prostate cancer. The goal is to see if a lower dose can still help while reducing side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with prostate cancer that has spread to other parts of the body (called metastatic).
- You took the drug enzalutamide between August 1, 2014, and December 31, 2023.
- You are 18 years or older.
- You have given permission (signed a consent form) to be part of the study.
- You do not have a serious heart condition, such as a recent stroke or heart attack, uncontrolled high blood pressure, or heart failure.
- You did not die within one month of starting enzalutamide.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding specific antibiotics (amoxicillin, metronidazole, vancomycin, ciprofloxacin) to enzalutamide can help treat advanced prostate cancer that has stopped responding to other treatments. It aims to see if changing gut bacteria can make the cancer therapy work better.
This study tests whether older men (75+) with advanced prostate cancer need a different dose of enzalutamide than younger patients. Enzalutamide is a hormone therapy that slows prostate cancer growth. The trial will help doctors give the safest, most effective dose for elderly patients.
This Phase 2 study tests whether adding ZEN003694 to enzalutamide works better than enzalutamide alone in men whose prostate cancer has spread and is no longer controlled by hormone lowering treatments. It focuses on people who either did not respond well to abiraterone (poor responders) or did respond (responders), then compares outcomes between treatment groups.
This trial tests a new drug (TYK-00540) combined with enzalutamide for men whose prostate cancer has spread and is no longer responding to standard hormone therapy. It may be an option if you have tried only one other newer hormone treatment and it failed.
This trial tests a combination of two oral drugs, relugolix and enzalutamide, in men with high-risk prostate cancer that hasn't spread to distant parts of the body. The goal is to see if this treatment can help control the cancer before or alongside local therapies like surgery or radiation.
This Phase 2 trial tests whether giving testosterone first, then enzalutamide (a prostate cancer hormone-blocking pill), can slow or prevent worsening metastatic prostate cancer. It is designed for men whose cancer progressed despite ongoing hormone-suppression treatment.
Hear when a new Prostate Cancer Metastatic Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.